Rheumatoid arthritis and pyoderma gangrenosum: a population-based case-control study

Author(s):  
Khalaf Kridin ◽  
Giovanni Damiani ◽  
Arnon D. Cohen
BMC Medicine ◽  
2019 ◽  
Vol 17 (1) ◽  
Author(s):  
Alyshah Abdul Sultan ◽  
Christian Mallen ◽  
Sara Muller ◽  
Samantha Hider ◽  
Ian Scott ◽  
...  

2020 ◽  
Vol 9 (6) ◽  
pp. 1626 ◽  
Author(s):  
Khalaf Kridin ◽  
Ralf J. Ludwig ◽  
Dana Tzur Bitan ◽  
Mouhammad Kridin ◽  
Giovanni Damiani ◽  
...  

The coexistence of pyoderma gangrenosum (PG) and gout has been reported in individual patients; however, the association between these conditions has not been investigated. We aimed to assess the association between PG and gout and to examine whether the presence of gout predisposes to the development of PG. A population-based case-control study was conducted comparing PG patients (n = 302) with age-, sex-, and ethnicity-matched control subjects (n = 1497) with respect to the presence of preceding gout. Logistic regression models were utilized for univariate and multivariate analyses. The prevalence of preceding gout was greater in patients with PG than in control subjects (3.7% vs. 0.7%, respectively; p < 0.001). Gout was associated with a more than fivefold increase in the risk of PG (OR, 5.15; 95% CI, 2.21–11.98). After adjusting for confounding factors, gout emerged as a significant independent predictor of PG (adjusted OR, 4.08; 95% CI, 1.69–9.80). Gout preceded the diagnosis of PG by a median latency of 4.6 years. Patients with gout-associated PG were older, predominantly male, and had a higher prevalence of metabolic syndrome than other patients with PG. In conclusion, gout increases the risk of developing PG by more than fivefold. Physicians managing patients with gout and PG should be aware of this emerging association.


2014 ◽  
Vol 66 (6) ◽  
pp. 844-851 ◽  
Author(s):  
Annmarie Wesley ◽  
Camilla Bengtsson ◽  
Eva Skillgate ◽  
Saedis Saevarsdottir ◽  
Töres Theorell ◽  
...  

PLoS ONE ◽  
2016 ◽  
Vol 11 (5) ◽  
pp. e0155956 ◽  
Author(s):  
Kaja Eriksson ◽  
Lena Nise ◽  
Anna Kats ◽  
Elin Luttropp ◽  
Anca Irinel Catrina ◽  
...  

2020 ◽  
Author(s):  
Khalaf Kridin ◽  
Giovanni Damiani ◽  
Ralf J Ludwig ◽  
Dana Tzur Bitan ◽  
Arnon D. Cohen

Abstract BackgroundUlcerative colitis (UC) is a well-known underlying comorbidity in pyoderma gangrenosum (PG). However, the relative risk conferred by UC for the subsequent development of PG is yet to be explicated.ObjectiveTo estimate the magnitude of the association between UC and the subsequent occurrence of PG, thus enabling to assess the PG risk with UC.MethodsA population-based case-control study was conducted comparing PG patients (n = 302) with age-, sex- and ethnicity-matched control subjects (n = 1,497) regarding the presence of UC. Logistic regression models were utilized for univariate and multivariate analyses.ResultsThe prevalence of UC was greater in patients with PG than in control subjects (7.3% vs. 0.5%, respectively; P < 0.001). A 15-fold increase in the odds of PG with UC (OR, 14.62 95% CI, 6.45–33.18) was observed. This association retained its statistical significance following a sensitivity analysis excluding UC cases diagnosed up to 2 years prior to PG (OR, 9.88; 95% CI, 3.91–24.97), and after adjusting for confounding factors (adjusted OR, 10.78; 95% CI, 4.55–25.52). The median latency between the diagnosis of UC and the development of PG was 4.59 years. Patients with both PG and UC were younger and had a lower prevalence of smoking when compared to the remaining patients with PG.ConclusionsUC increases the odds of developing PG by 15-folds. Physicians managing patients with UC should be aware of this increased burden. Patients with UC may be advised to avoid additional precipitating factors of PG.


Sign in / Sign up

Export Citation Format

Share Document